New RSV vaccine trial targets High-Risk adults in japan
NCT ID NCT07543380
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an RSV vaccine in adults aged 18-59 who have health conditions like chronic lung, heart, or kidney disease that put them at higher risk for severe RSV. The goal is to see if the vaccine triggers a strong immune response and is safe. Participants receive one shot and are followed for about 2 months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS (RSV) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fukuwa Clinic
RECRUITINGChuo-ku, Tokyo, 104-0031, Japan
-
Nihonbashi Sakura Clinic
RECRUITINGChuo-ku, Tokyo, 103-0025, Japan
-
Tenjin Sogo Clinic
RECRUITINGFukuoka, 810-0021, Japan
-
Tokyo-Eki Center-building Clinic
RECRUITINGChuo-ku, Tokyo, 103-0027, Japan
-
Tsuchiura Beryl Clinic
RECRUITINGTsuchiura, Ibaraki, 300-0062, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One shot, two viruses? new mRNA vaccine targets RSV and hMPV
- New mRNA vaccine aims to shield against RSV
- Massive RSV vaccine study uses real-world data to see if shots prevent severe illness
- New RSV vaccine aims to shield adults from severe respiratory infection
- Scientists test RSV vaccine to boost immune memory
- New study tracks RSV in pregnant women and their babies